The first official BCL-2 inhibitor was ABT-737, which has a high affinity for BCL-2, BCL-xl, and BCL-w and results in significant follicular lymphoma (FL) and CLL cell death in vitro [12]. This evidence concerns the gene BCL2 and follicular lymphoma.